This study is testing a new treatment for people with *Macular Neovascularization (MNV)*, a condition where new blood vessels grow under the retina, often due to Age-Related Macular Degeneration (AMD). The treatment involves a single shot, called an **Intravitreal (IVT) Injection**, into the eye to help prevent vision loss. The trial is **Phase 3**, which means it is in the later stages of testing to make sure it works well and is safe. To join, participants need to be **50 years or older** and have MNV linked to AMD, with a history of certain eye treatments. Key points to consider: - **Study Length and Visits:** This trial requires visits to the clinic for screening and monitoring. - **Eligibility:** Participants must have shown improvement from previous treatments, and there are specific criteria about eye health. - **Risks:** There are some health conditions and treatments that could disqualify you from participating. A doctor will help determine if you're a good fit. This study aims to improve care for those with vision problems from AMD.